Medical device regulatory reform: Insights from the watchman left atrial appendage closure technology for stroke prophylaxis in atrial fibrillation

Archives of Internal Medicine

Volumn 171, Issue 18, 2011, Pages 1670-1672

  Cingolani, Eugenio ^a   Stevens, Steven ^a   Shehata, Michael ^a   Diamond, George A ^a   Kaul, Sanjay ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR RISK; CLINICAL PRACTICE; DEVICE APPROVAL; DEVICE RECALL; DEVICE SAFETY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE POLICY; HEART ASSIST DEVICE; HEART ATRIUM APPENDAGE; HEART ATRIUM FIBRILLATION; HUMAN; NOTE; PRIORITY JOURNAL; STROKE;

ATRIAL APPENDAGE; ATRIAL FIBRILLATION; CARDIAC SURGICAL PROCEDURES; DEVICE APPROVAL; HEALTH CARE REFORM; HUMANS; PROSTHESES AND IMPLANTS; PROSTHESIS DESIGN; STROKE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 80054731109     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2011.329     Document Type: Note

References (20)

1. Holmes DR, Reddy VY, Turi ZG, et al.; PROTECT AF Investigators. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet. 2009;374(9689):534-542.
2. O'Riordan M. FDA advisory panel votes 7 to 5 to recommend approval of Watchman LAA closure device. http://www.theheart.org/article/962955 .do. Accessed January 8, 2011.
3. O'RiordanM.Watchman delayed: FDA wants more data on the LAA-closure device before approving. http://www.theheart.org/article/1060779.do. Accessed January 8, 2011.
4. Campbell G. Statistics in the world of medical devices: the contrast with pharmaceuticals. J Biopharm Stat. 2008;18(1):4-19.
5. US Food and Drug Administration. Medical device classification procedures. http://www .accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR /CFRSearch.cfm?CFRPart=860&showFR=1. Accessed January 8, 2011.
6. McCabe DJ, Kinsella JA, Tobin WO. Left atrial appendage occlusion in non-valvular atrial fibrillation. Lancet. 2009;374(9689):504-506.
7. Maisel WH. Left atrial appendage occlusion: closure or just the beginning? N Engl J Med. 2009; 360(25):2601-2603.
8. WATCHMAN@ LAA Closure Technology, Atritech, Inc. FDA executive summary memorandum: prepared for the April 23, 2009 meeting of the Circulatory System Devices Advisory Panel. http://www.fda.gov/ohrms/dockets/ac/09/briefing /2009-4434b1-01%20f.pdf. Accessed January 8, 2011.
9. Dhruva SS, Bero LA, Redberg RF. Strength of study evidence examined by the FDA in premarket approval of cardiovascular devices. JAMA. 2009; 302(24):2679-2685.
10. Kramer DB, Mallis E, Zuckerman BD, Zimmerman BA, Maisel WH. Premarket clinical evaluation of novel cardiovascular devices: quality analysis of premarket clinical studies submitted to the Food and Drug Administration 2000-2007. Am J Ther. 2010;17(1):2-7.
11. Garber AM.Modernizing device regulation. N Engl J Med. 2010;362(13):1161-1163.
12. US Dept of Health and Human Services; Food and Drug Administration, Center for Devices and Radiological Health, Office of Device Evaluation; Center for Biologics Evaluation and Research. The Least Burdensome Provisions of the FDA Modernization Act of 1997: Concept and Principles: Final Guidance for FDA and Industry. http://www.fda .gov/MedicalDevices/DeviceRegulationandGuidance /GuidanceDocuments/ucm085994.htm. Accessed January 8, 2011.
13. Mundy A, Favole JA. FDA rips approval of medical device. Wall Street Journal. September 25, 2009:§A:4.
14. Avorn J. Regulation of devices. BMJ. 2010;341(1): c5730. doi:10.1136/bmj.c5730.
15. Zuckerman DM, Brown P, Nissen SE. Medical Device Recalls and the FDA Approval Process. Arch Intern Med. 2011;171(11):1006-1011.
16. California Healthcare Institute. Upcoming changes to the 510(k) process: new approval pathways and the impact on medical device development and innovation. http://chi.org/uploadedFiles/Industry -at-a-glance/CHI-510K-White- Paper-FINAL .pdf. Accessed January 8, 2011.
17. Kaul S, Shah PK, Diamond GA. As time goes by: current status and future directions in the controversy over stenting. J Am Coll Cardiol. 2007; 50(2):128-137. (Pubitemid 47002183)
18. Kong DF, Hasselblad V, Krucoff MW. Evidence strength in FDA premarket approval of cardiovascular devices. JAMA. 2010;303(16):1599-1600.
19. Hamburg MA. Shattuck lecture. Innovation, regulation, and the FDA. N Engl J Med. 2010;363 (23):2228-2232.
20. Diamond GA, Kaul S. Evidence-based financial incentives for healthcare reform: putting it together. Circ Cardiovasc Qual Outcomes. 2009;2(2): 134-140.